Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment

• DOI: 10.1007/s00262-023-03593-2
• Publication Date: 2024-01-18T12:01:32Z
• Authors: Joanna Baginska; Allison Nau; Ilana Gomez Diaz; Anita Giobbie-Hurder; Jason Weirather; Juliana Vergara; Charlotte Abrecht; Margaret Hallisey; Jenna Dennis; Mariano Severgnini; Julia Huezo; Isabella Marciello; Osama Rahma; Michael Manos; Andrew S. Brohl; Philippe L. Bedard; Daniel J. Renouf; Elad Sharon; Howard Streicher; Patrick A. Ott; Elizabeth I. Buch...; F. Stephen Hodi
• Keywords: Vascular Endothelial Growth Factor A; 0301 basic medicine; Receptors, Vascular Endothelial Growth Factor; 0302 clinical medicine; Research; Recombinant Fusion Proteins; Leukocytes, Mononuclear; Humans; Antibodies, Monoclonal, Humanized; Melanoma

Abstract Background Vascular endothelial growth factor is associated with reduced immune response and impaired anti-tumor activity. Combining antiangiogenic agents with immune checkpoint inhibition can overcome this immune suppression and enhance treatment efficacy.

Methods This study investigated the combination of ziv-aflibercept anti-angiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Baseline and on-treatment plasma and PBMC samples were analyzed by multiplex protein assay and mass cytometry, respectively.

Results In this Phase 1B study (NCT02298959), ten patients with advanced PD-1-resistant melanoma were treated with a combination of ziv-aflibercept (at 2–4 mg/kg) plus pembrolizumab (at 2 mg/kg), administered intravenously every 2 weeks. Two patients (20%) achieved a partial response, and two patients (20%) experienced stable disease (SD) as the best response. The two responders had mucosal melanoma, while both patients with SD had ocular melanoma. The combination therapy demonstrated clinical activity and acceptable safety, despite the occurrence of adverse events. Changes in plasma analytes such as platelet-derived growth factor and PD-L1 were explored, indicating potential alterations in myeloid cell function. Higher levels of circulating CXCL10 in non-responding patients may reflect pro-tumor activity. Specific subsets of γδ T cells were associated with poor clinical outcomes, suggesting impaired γδ T-cell function in non-responding patients.

Conclusions Although limited by sample size and follow-up, these findings highlight the potential of the combination of ziv-aflibercept antiangiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment and the need for further research to improve outcomes in anti-PD-1-resistant melanoma.

Trial registration number NCT02298959.